CD34 and acute myeloid leukemia: In our study, which we focused entirely on a homogeneous patient cohort of adults with AML receiving HLA-matched related or unrelated donor allografts after MAC, we found evidence of a statistically significant, and likely clinically meaningful, association between higher CD34+ cell dose and improved relapse risk, RFS, and OS.